Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9GZR7
UPID:
DDX24_HUMAN
Alternative names:
DEAD box protein 24
Alternative UPACC:
Q9GZR7; E7EMJ4; Q4V9L5
Background:
ATP-dependent RNA helicase DDX24, also known as DEAD box protein 24, plays a crucial role in RNA metabolism, including RNA splicing, editing, and degradation. Its ability to remodel RNA structures by utilizing ATP underscores its importance in cellular processes.
Therapeutic significance:
Understanding the role of ATP-dependent RNA helicase DDX24 could open doors to potential therapeutic strategies. Its pivotal function in RNA metabolism makes it a target of interest in the development of drugs aimed at modulating RNA-related diseases.